AID Genomics is a company dedicated to improving people's lives by making genomic medicine accessible. They are committed to providing better access to accurate diagnostics and equipping physicians with state-of-the-art diagnostics to enable better treatment choices for patients worldwide. Their research and development division integrates advanced technologies like next-generation sequencing (NGS), miRNA, epigenetics, and AI-based analytical tools. The company maintains strong and diverse partnerships to deliver affordable precision medicine, aiming to enhance patient care and quality of life.

AID Genomics specializes in redefining cancer care, emphasizing early cancer detection, using artificial intelligence analytics to improve patient diagnostics, and developing innovative and affordable genomic tests to extend and improve the quality of patients' lives. They are pioneers in genomic and genetic diagnostics, promoting individualized diagnostics and personalized medicine.

The Executive Chairman, Kelvin Wu, emphasizes that genomic testing should be a fundamental part of patient care, as it can provide quick and reliable analysis of circulating tumor DNA and RNA in patients' blood. This technology aids physicians in making informed therapy choices and managing patients effectively.

AID Genomics works with oncologists, providing them with tests that align each patient's unique cancer genomic profile with the right targeted therapy. They also support patients by offering detailed genomic insights for personalized care plans. Additionally, they partner with organizations to utilize robust datasets, advancing genomic science and their vision of accessible precision medicine solutions for patients.